Siponimod

Drug Profile

Siponimod

Alternative Names: BAF-312

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Dermatomyositis; Polymyositis
  • Phase I Liver failure; Renal failure

Most Recent Events

  • 31 May 2017 Novartis intends to make regulatory submissions for siponimod for secondary progressive Multiple sclerosis in 2018
  • 21 Apr 2017 Interim immunogenicity data from a phase III AMS04 trial in Multiple sclerosis presented at the (69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Feb 2017 Novartis Pharmaceuticals terminates a phase II trial in Polymyositis in USA, Belgium, Czech Republic, Hungary, Taiwan, Canada and Poland (NCT01801917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top